MedWatch

Novo-CFO: Here is the timeframe for Tresiba

The CFO of Novo Nordisk, Jesper Brandgaard, explains more about the ongoing dialogue with the FDA in regards to additional studies of diabetes drug Tresiba, and reveals what the US sales force will be used for until the time of approval.

Best case scenario three years, worst case scenario five years. Those are the prospects for the US launch of long-acting insulin product Tresiba, Novo Nordisk CFO, Jesper Brandgaard, explains in connection with the publication of the company’s financial report for Q1 2013.

“We hope CV (Cardio-Vascular) studies can begin within a year and then we hope to have the interim analysis of the studies within two to three years. And then we assume we can have an answer from the FDA on the resubmission within six months,” he says and adds:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier